High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients

Yu Ting Hsieh, Bing Juin Chiang, Chia Chang Wu, Chun Hou Liao, Chia Da Lin, Chung Hsin Chen

Research output: Contribution to journalArticlepeer-review

Abstract

To assess the predictive value of tumor burden on the biochemical response, and radiological response in Taiwanese metastatic castration-resistant prostate cancer (mCRPC) patients receiving enzalutamide. The mCRPC patients treated with enzalutamide were recruited from three hospitals. High tumor burden (HTB) was classified as metastases at either appendicular bone or visceral organ. Good prostate-specific antigen (PSA) response was defined as PSA reduction of 80%. In this cohort, there were 104 (54.2%) HTB patients and 88 (45.8%) with low tumor burden (LTB). Compared to LTB patients, fewer HTB patients had good PSA response (odds ratio: 0.43, range: 0.22–0.87, p = 0.019) and fewer radiological response (complete and partial remission) (odds ratio: 0.78, range: 0.36–1.68, p = 0.52) to enzalutamide. The disease control rate which also contained stable disease, was still lower in HTB (76.0%) than LTB group (92.9%, OR: 0.24, range: 0.07–0.77, p = 0.016) in the multivariable model. In addition, HTB patients had significantly shorter progression– free survival duration than did LTB patients (median: 8.3 vs. 21.6 months, log-rank test p = 0.003) in the univariable analysis. The tumor burden before the use of enzalutamide was associated with treatment outcomes. HTB reduced PSA response rate, radiological response rate and progres-sion-free survival duration.

Original languageEnglish
Article number3966
JournalCancers
Volume13
Issue number16
DOIs
Publication statusPublished - Aug 2 2021

Keywords

  • Enzalutamide
  • Prognosis
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Tumor burden

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients'. Together they form a unique fingerprint.

Cite this